Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of nOPV1 and nOPV3 in Healthy Adults
NCT04529538Phase 1Completed
- Sponsor
- PATH
- Start
- Mar 2021
- Primary completion
- Feb 2023
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of Novel oral polio vaccine type 1 and novel oral polio vaccine type 3 in poliomyelitis (8 arms), sponsored by PATH. Primary endpoints: Serious Adverse Events, Solicited Adverse Events and 1 more. Started Mar 2021; status: completed.
02
Drugs
Novel oral polio vaccine type 1novel oral polio vaccine type 3
03
Conditions
poliomyelitis
Beyond the preview
Go deeper on NCT04529538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04529538.